This technology harnesses the power of patients» very immune cells — which are extracted from them, reengineered in a lab, and then pumped back into the body — to
kill aggressive blood cancers.
It's the first CAR - T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for
certain aggressive blood cancers.
Chimeric antigen receptor (CAR) T cell therapy, which edits a cancer patient's T cells to recognize their tumors, has successfully helped patients
with aggressive blood cancers but has yet to show the ability to treat solid tumors.
In equatorial Africa, a region of the globe known as the «lymphoma belt,» children are ten times more likely than in other parts of the world to develop Burkitt's lymphoma, a
highly aggressive blood cancer that can be fatal if left untreated.
AML is
an aggressive blood cancer characterised by an accumulation of dysfunctional blood cells in the body, and AML diagnosis is often associated with poor survival.
«Targeting cancer without destroying healthy T - cells: Unique approach to treatment of rare and
aggressive blood cancers.»
Take recent research into T cell acute lymphoblastic leukemia,
an aggressive blood cancer.
George Goldner and Nancy Krieg brought Nemo to Cornell's large animal hospital in 2013 for treatment of lymphoma,
an aggressive blood cancer.